Skip to content

Use and adverse effects profile of dextromethorphan-bupropion versus escitalopram in treatment of depression

Effectiveness and safety of Dextromethorphan-bupropion versus Escitalopram in treatment of major depressive disorder - NIL

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094893
Enrollment
86
Registered
2025-09-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate

Interventions

Intervention1: DRUG: DEXTROMETHORPHAN BUPROPION Control Intervention1: DRUG: ESCITALOPRAM

Sponsors

TEJASWI P
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients willing to give written informed consent 2 Newly diagnosed patients with major depressive disorder of either sex aged between 18 and 65 years and a current episode of major depressive disorder 3 Diagnosis will be made based on DSM 5 criteria 4 A minimum score of more than or equal to 25 on Montgomery-Asberg depression rating scale MADRS 5 Minimum score of more than or equal to 4 on clinical global impression severity scale CGI S

Exclusion criteria

Exclusion criteria: 1 Pregnant or lactating females 2 Patients with medical conditions like hepatic or renal failure 3 Past history of any cardiac disease 4 History of bipolar disorder 5 History of panic disorder 6 History of obsessive compulsive disorder 7 History of treatment resistance depression defined as having at least two failed adequate antidepressants treatments in current major depressive episode 8 History of psychotic disorder 9 Clinically risk of suicide assessed by C SSRS 10 History of seizures 11 Patients on treatment with any other drugs which are CYP2D6 inducers or inhibitors

Design outcomes

Primary

MeasureTime frame
The primary efficacy variable will be the change in MADRS total score from baseline to week 6Timepoint: 6 WEEKS

Secondary

MeasureTime frame
1 Reduction more than or equal to 50% from baseline in MADRAS total score known as clinical response 2 MADRS total score less than or equal to 10 known as clinical remission 3 Score on clinical global impression severity scale 4 Score on clinical global impression improvement scale 5 Quick inventory of depression symptomology score known as QIDS SR scoreTimepoint: 6 weeks

Countries

India

Contacts

Public ContactDr VIJAYAKUMAR A E

ESIC MEDICAL COLLEGE AND PGIMSR

aevijay1985@gmail.com8695032720

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026